Clinique ovo
Montreal, Quebec, H4P 2S4, Canada
NCT Number: NCT06279715
IVF is the most commonly employed form of assisted reproductive technologies (ART) for the 10-15% of couples who face difficulties becoming pregnant. Many individuals elect to have their IVF-derived embryos analyzed using pregenetic implantation testing for aneuploidies (PGT-A). The use of PGT-A is particularly beneficial for patients at higher risk for aneuploidy, such as those of advanced maternal age and those faced with recurrent pregnancy loss or recurrent implantation failure.
Segmental aneuploidies are generated when a small piece of a chromosome is gained or lost during cell division, resulting in subchromosomal copy number (CN) changes. The frequency of segmental aneuploidies during the cleavage stage varies between studies, from as low as 3.9% to 15% and up to 70 % with no reported correlation with maternal age. This can be explained by the fact that, unlike whole chromosome aneuploidies, segmental aneuploidies most often involve paternally inherited chromosomes.
Looking for future studies?
Notify Me18 year–43 year
All sexes
Observational
Montreal, Quebec, H4P 2S4, Canada
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PGT-A typically involves the biopsy of three to eight cells from the developing embryo after approximately five days of culture. This technology also allows for the identification of segmentally aneuploid embryos.
Time frame: Up to 3 weeks after embryo fertilization
Segmental aneuploidy is associated with high levels of sperm DNA fragmentation index
Clinique Ovo
Industry
Evaluation of the Association Between the DNA Fragmentation Index (DFI) and the Frequency of Segmental and Total Aneuploidies
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03354013
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Embryo
Ghent, East-Flandres, Belgium
View Trial DetailsNCT04574310
Embryo Disorder
View Trial Details